Eris Lifesciences and Natco Pharma Partner to Launch Semaglutide in India

Eris Lifesciences has partnered with Natco Pharma to commercialise semaglutide, a GLP-1 receptor agonist used in managing Type 2 diabetes and chronic weight management, in India. Following Natco's recent regulatory approval to manufacture generic semaglutide, the companies plan a launch in March 2026. The collaboration combines Eris's commercial expertise and Natco's manufacturing capabilities to address India's growing metabolic care needs amid an increasingly competitive market following the drug's patent expiry.